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Abstract 
Immunosuppression can be discontinued from selected and stable patients after 
liver transplantation resulting in spontaneous operational tolerance (SOT), 
although the underlying mechanisms remain elusive. Thus we analyzed serial liver 
biopsies from adult liver recipients enrolled in a prospective multi-center 
immunosuppression withdrawal trial employing immunophenotyping and 
transcriptional profiling. Liver samples were collected before the initiation of 
weaning, at time of rejection, or 1 and 3 years after complete drug discontinuation. 
Unexpectedly the tolerated grafts developed portal tract expansion with increased 
T cell infiltration after immunosuppression withdrawal. This was associated with 
transient and preferential accumulation of CD4+FOXP3+ cells and a trend towards 
up-regulation of immune activation and regulatory genes, without signs of 
rejection. At the same time no markers of endothelial damage or activation were 
noted. Portal infiltrates persisted at 3 year, but were characterized by decreased 
expression of genes associated with chronic immunological damage. Furthermore 
SOT was not associated with a progressive liver fibrosis up to five years. These 
data suggest that SOT involves several mechanisms: a long-lasting local immune 
cell persistence with a transient regulatory T cells accumulation followed by a 
down-regulation of immune activated genes over years. These results have 
important implications for designs and follow-up of weaning trials.  
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Introduction  
Most human liver transplant recipients require lifelong immunosuppression (IS) to 
prevent immune-mediated graft damage, which is associated with relevant clinical 
complications like infection, malignancies, renal dysfunction and metabolic 
disturbances, that contribute to the stagnation of long term survival outcomes (1). 
Years after transplantation, however, selected liver recipients can discontinue IS 
and maintain normal graft function, a phenomenon known as spontaneous 
operational tolerance (SOT)(2). Liver transplantation exhibits lower graft loss from 
rejection episodes and by far the highest rates of SOT as compared with other 
solid organ transplantation settings (2-4). The immune privileged status of liver 
allografts is even more clearly displayed in animal models (e.g. mice, rats, dogs 
and pigs), in which the default outcome of allogeneic liver transplantation in the 
absence of IS tends to be spontaneous acceptance rather than rejection (5-7). The 
mechanisms responsible for allograft tolerance in these models are not completely 
understood, but lack of immune response against the liver is clearly not the cause. 
Instead, the allogeneic liver rapidly activates alloreactive T cells, which then 
infiltrate the graft and induce pathologic changes resembling mild rejection. This is 
followed by deletion of the activated alloreactive T cells via apoptosis or 
emperipolesis, and generation of regulatory T cells (Tregs), which restore 
homeostasis and establish donor-specific tolerance (8). Whether similar 
mechanisms are responsible for the development of SOT in human transplantation 
is unknown. 
Studies focused on the characterization of SOT patients identified changes in both 
peripheral blood and liver tissue. Thus, as compared with patients under 
maintenance IS, SOT patients displayed increased numbers of circulating 
CD4+CD25+ Tregs, γδ T cells, and a higher ratio of Vδ1/Vδ2 or pDC2/pDC1 cells 
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(9-14). Likewise some studies reported that liver biopsies of SOT patients 
contained more FOXP3+ cells than patients under IS (15, 16). 
Two recent prospective IS withdrawal trials in selected adult and pediatric patients, 
respectively, have been particularly informative, demonstrating that SOT is more 
prevalent than previously estimated (40 to 60% of enrolled patients)(17-19), but 
only in patients in whom IS withdrawal is attempted late after transplantation. 
Furthermore, at least in adults, successful IS withdrawal is also independently 
associated with recipient age. These data suggest that gradual attrition of the 
alloreactive T cell pool over several years through exhaustion/senescence may be 
required to achieve SOT. The adult study also revealed that the use of intrahepatic 
transcriptional biomarkers predicted the outcome of IS withdrawal (17) much more 
accurately than any combination of peripheral blood biomarkers. The need to 
study the graft as opposed to blood is further emphasized by the observation that 
during acute cellular rejection (ACR) Treg frequencies are differentially regulated 
between blood (reduced/normal) and liver allografts (increased) (20, 21), and that 
in a humanized mouse model the ability of Tregs to home into the allograft is 
indispensable to induced tolerance (22). 
To investigate the immune regulatory mechanisms elicited by IS withdrawal, in the 
current study we longitudinally analyzed the distribution of intrahepatic T cell 
subsets and gene expression patterns in protocol liver biopsies obtained from 
operationally tolerant liver recipients before, 1 and 3 years after successful IS 
withdrawal.  
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Materials and Methods 
Subjects 
Biological samples were obtained from liver recipients enrolled in a previously 
reported prospective multicenter trial of IS withdrawal (clinicaltrials.gov 
identification NCT00647283) (17, 18). Briefly, IS doses were gradually decreased 
until complete discontinuation over 6-9 months. Patients were then followed-up for 
60 additional months. Protocol liver biopsies were obtained in all patients at 
baseline (before IS withdrawal), 1 and 3 years and in a subgroup at 5 years after 
successful drug withdrawal (in SOT recipients), and at the time of rejection (in non-
tolerant recipients). Patients who did not develop rejection were classified as SOT 
as long as IS cessation was maintained for at least 12 months with stable liver 
function and no histopathologic evidences of acute and/or chronic rejection. Out of 
the 102 recipients participating in the trial, IS withdrawal was successful in 41 
recipients. For the current study, we selected a subgroup of 24 SOT recipients 
from whom sequential liver biopsies and blood samples were available for immune 
phenotype (n=18 for immunohistology and 12/18 for additional flow cytometry) 
and/or transcriptional (n=17) analyses (Suppl. Tab. 1). Gene expression analyses, 
were also performed in a group of 14 non-tolerant recipients before IS withdrawal 
and while undergoing rejection. Only hepatitis C virus (HCV) negative patients 
enrolled at Hospital Clinic Barcelona were employed for these analyses. 
Characteristics and clinical data of patients whose samples were employed are 
summarized in Table 1. This study was approved by the local research Ethics 
Committee of all participating institutions and written informed consent was 
obtained from each patient.  
 
Liver biopsy specimens 
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Liver biopsies were performed percutaneously under local anesthesia. A 2- to 3-
mm portion of the needle biopsy was immediately preserved in RNAlater reagent 
(Ambion), kept at 4°C for 24 hours, and then at -80oC after removal of the 
RNAlater. The remaining cylinder was formalin fixed and paraffin embedded 
(FFPE).  
 
Histological assessment of liver biopsies 
For histological assessment, 3-µm thick slides were stained using hematoxylin and 
eosin, Masson’s trichrome for connective tissue analysis. All histo-pathological 
examinations were performed by the same pathologist, who was blinded to all 
clinical and biological data.  
 
Immunohistological methods 
Intrahepatic immunophenotyping was performed as previously published (17, 20, 
23). We determined the portal infiltrate size by encircling portal infiltrates along the 
limiting plate and excluded the lumen of veins, arteries and bile ducts (Fig. 1A).  
We histologically analyzed the intrahepatic infiltration of CD4+CD8-FOXP3- (CD4+), 
CD8+CD4-FOXP3- (CD8+), CD4+CD8-FOXP3+ (CD4+FOXP3+ Tregs) and 
CD8+CD4-FOXP3+ (CD8+FOXP3+) cells (Fig. 1). In the current study 96.1% of 
portal FOXP3+ cells were CD4+, and only 3.9% were potentially activated 
CD8+FOXP3+ Teff, excluding a significant contamination of activated Teff in the 
pool of CD4+FOXP3+ Tregs. The Treg detection via immunofluorescence of 
human FFPE tissue was recently validated by employing flow cytometry and 
epigenetic analysis(20, 23).   
 
Flow cytometry 
 10 
 
Flow cytometry immunophenotyping of whole blood samples was performed in a 
subset of 12 recipients from whom sequentially collected specimens were 
available (17). Titrated amounts of fluorochrome-conjugated monoclonal 
antibodies were employed to identify CD4+ and CD8+ T cells and Tregs  (Suppl. 
Fig 1, Tab. 3). Cells were fixed in 1% paraformaldehyde/PBS, and data were 
acquired on a BD FACSCanto (BD) and analyzed employing FlowJo software 
(Tree Star). 
 
Liver tissue RNA extraction and processing 
Total RNA were extracted according to the TRIzol manufacturer’s protocol 
(Invitrogen). Quality and quantity were assessed with the Agilent 2100 Bioanalyzer 
(Agilent Technologies) and Nanodrop ND-1000, respectively. DNA was removed 
from total RNA preparations using Turbo DNA-free DNAse treatment (Ambion) 
and RNA was then reverse transcribed into cDNA using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). Gene lists were taken from our 
previous publication and the published results of the “Molecular Microscope 
System” from the “Alberta Transplant Applied Genomic Centre”  
(http://atagc.med.ualberta.ca/Research/GeneLists/Pages/default.aspx) (17, 24). A 
pre-amplification of cDNA over 10 cylces was performed using pooled TaqMan 
Assays and the TaqMan PreAmp Master Mix following manufacturer's protocol. 
qPCR was performed using the 48.48 Dynamic Array following manufacturer's 
protocol using a BioMark (both Fluidigm Corporation, CA, USA). To quantify 
transcript levels, target gene Ct values were normalized using Ct values of HPRT1 
as a reference gene to generate -∆Ct values.  
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Statistical analysis 
Statistical analysis was performed in R (http://www.R-project.org.). Sequential 
samples from SOT patients were compared using linear mixed-effects models 
(nlme package) with a random effect for intercept. This approach accounted for 
repeated measurements and for missing data. The study design was balanced 
with data collected at similar time-points but complete datasets for all time-points 
were not available in all patients (Suppl. Tab. 1). A global p-value derived from 
likelihood ratio test was used to evaluate the total effect of time for each model. 
Extreme outliers were detected using Bonferroni outlier test (car package) and 
were re-coded to the next highest or next lowest value in the corresponding time-
point group depending on the direction of the extreme value. For the analysis of 
Infiltrate Size data were log transformed (ln) to account for a skewed distribution at 
3 years SOT. Bonferroni correction was used to adjust p-values derived from 
multiple comparisons. 
Comparison between paired pre-weaning and rejector samples was performed 
with paired t-tests using GraphPad Prism 6 software. Fold-differences for gene 
expression data were calculated according to the comparative CT method (2-∆∆CT 
method). P-values <0.05 (two-tailed) were considered statistically significant in all 
analyses. 
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Results 
The development of operational tolerance is currently being tested in several 
clinical trials. In order to gain a better understanding of the mechanisms of 
operational tolerance, we evaluated serial liver biopsies of tolerant patients for 
composition of the immune infiltrates (Fig. 1). Furthermore, to elucidate the 
functional aspects of intrahepatic immune responses the quantitative 
immunophenotypic analysis was paralleled by intrahepatic gene expression 
analysis.  
To our surprise we detected increased portal infiltrates one and three years after 
complete IS withdrawal in patients with normal transaminases (Fig. 2A). We 
already reported on mild portal inflammation and lymphocytic cholangitis at one 
year in our previous analysis (18). However, the current quantitative analysis 
revealed significant changes one and three yearsof SOT (Fig. 1A, Fig. 2A, Table. 
2). These changes were significantly milder than those observed in non-tolerant 
recipients at the time of rejection and did not fulfill Banff criteria for rejection. 
Furthermore, portal infiltrate size was associated with the elapsed time post-
withdrawal (p=0.002) (Tab. 2, Fig. 2A). The assessment of portal tract expansion 
by conventional semi-quantitative histological scores was too insensitive to detect 
these longitudinal differences (Suppl. Tab. 2).  
Longer follow-up liver biopsies at 5 years SOT were only available in a subgroup 
of 5 patients (Suppl. Tab. 1). The progression of the fibrosis score (F1 to F2) from 
3 to 5 years post withdrawal was noted in 1 patient, although this was not 
associated with increased portal or lobular inflammatory infiltrates. No changes in 
fibrosis were noted in the remaining 4 patients in this time interval. Furthermore 
anti-donor HLA antibodies, that were assessed in about 80% of the patients in the 
initial study (18), were only detectable in 3 tolerant patients with sequential liver 
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biopsies.  
T cells accumulated in the portal tracts and were almost absent in the liver lobules. 
Longitudinal analyses of the portal T cell infiltration showed a significant 
accumulation of CD4+FOXP3+ Tregs expressed as the portal Treg density at 1 
year SOT (Fig. 2B) with a significant reduction of the portal Treg/CD4+ and 
Treg/CD4++CD8+ ratios from 1 year to 3 years SOT (Fig. 2C, Tab. 2). The CD4+ 
and CD8+ effector T cell densities varied insignificantly (Fig. 2D). However, we 
noticed a trend to an increased  CD4+/CD8+ ratio at 3 years SOT, which is a 
marked contrast to the decreased CD4+/CD8+ ratio observed  during ACR (20). 
The longitudinal changes of portal T cell infiltration pattern were not reflected by 
the longitudinal changes in all available blood samples underlining the importance 
to study cellular and molecular changes directly in the graft (Tab. 3, Suppl. Fig. 1, 
Fig. 2E).  
As liver cell immunohenotyping does not allow us to draw functional conclusions, 
we complemented the data with transcript levels of a set of 48 genes known to be 
involved in allograft rejection, immune regulation, and graft endothelium 
activation/damage (24) (Table 4). Analysis of liver samples obtained from tolerant 
recipients before and after successful IS-withdrawal revealed significant changes 
in pro-inflammatory, immune regulatory and endothelial-related genes (Table 4, 
Fig 3, Suppl. Tab. 3).  
The expression of FOXP3 followed the same pattern as the portal CD4+FOXP3+ 
Tregs in the immunohistology analyses, with a significant transient increase at 1 
year post-drug withdrawal, and a subsequent return to the pre-weaning levels at 3 
years post-withdrawal (p=0.013 and 0.003, respectively) (Fig. 3A). Two other 
immune regulatory genes, PD1 and BATF, showed a non-significant increase in 
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expression at 1 year post-withdrawal followed by a significantly decreased 
expression at 3 years SOT (Table 4, Suppl. Tab. 3).  
From 20 rejection-associated genes analyzed, only IL32 transcript levels 
significantly increased 1-year post-withdrawal as compared with baseline (Fig. 
3B). In contrast, all other genes known to be associated with rejection were not 
significantly increased or their expression significantly dampened after 3 years 
post-withdrawal (e.g. CD52, CD68, STAT1 and GPNMB) (Table 4, Fig. 3B). In 
comparison, the expression of CXCL10, CXCL9, UBD, IRF1 and STAT1 was 
significantly increased in the liver biopsies collected at the time of rejection in non-
tolerant recipients compared to paired pre-weaning levels (Table 4, Suppl. Tab. 3). 
On the basis of the expression of endothelial-related genes, the inflammatory 
changes noted in tolerant patients over time were not associated with endothelial 
damage and/or activation. Thus, S1PR1, RGS5, ENPP2, MSL3, OPN3, PAK2, 
CDH5 and SELP transcript levels significantly decreased post-withdrawal (Fig. 3C, 
Table 4). 
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Discussion 
This study offers the first longitudinal assessment of intrahepatic cellular and 
molecular immune regulatory mechanisms during the development of SOT after 
human liver transplantation.  
The inflammatory changes and Treg enrichment within the graft reported here 
have also been seen with a much shorter time scale in animal models of 
spontaneous liver transplant tolerance (5-7, 25). Likewise Gagliani et al. found a 
transient increase of Treg frequencies first in the blood (up to 3 weeks) and later a 
transient accumulation in islet allografts (day 30), that decreased two-fold by day 
150, after a tolerance induction protocol (26). The presence of inflammatory 
mononuclear infiltrates enriched in Tregs has also been observed in tolerized skin 
allografts (unpublished data). However, all those changes in animal models 
occurred relatively early after transplantation fueling the notion that tolerance 
induction can be achieved quickly after transplantation. Furthermore, tolerance 
induction in animals was described as a fast and transient process. In contrast, our 
data of SOT patients creates a different picture of tolerance induction in humans: 
SOT was more likely to occur in patients with prolonged time (years) after 
transplantation (18). Expanded portal infiltrates potentially controlled by Tregs was 
still seen one year post-withdrawal and the down-regulation of endothelial 
activation and immune response associated genes were just observed three years 
post-withdrawal. Even at three years inflammatory portal infiltrates were still not 
resolved suggesting ongoing immunological activity in the graft. However, this did 
not lead to endothelial activation, rejection, graft fibrosis or development of donor-
specific humoral immune responses, suggesting a balanced immune response 
without graft damage. Our data do not exclude the contribution of other regulatory 
mechanisms including e.g. other regulatory cell types like Tr1 cells or innate 
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lymphoid cells at any time point. These observations will be important for future 
tolerance inducing trials in humans. First, trials need prolonged monitoring with 
inclusion of protocol graft biopsies. Second, immuno-interventions promoting 
active immunoregulation within the graft are likely to synergize with the natural 
tolerogenic pathways elicited following immunosuppression discontinuation. Third, 
immunointerventions are more likely to be successful after a long period of time 
following transplantation.  
Although the observation that FOXP3+ cells accumulate in the liver grafts of SOT 
was reported previously (15, 16), the interpretation of the data was compromised 
by the fact that drug-free patients were compared with liver recipients on 
calcineurin inhibitor-based maintenance IS, which is known to affect Treg numbers 
(27). Furthermore, longitudinally collected liver biopsy information was not 
available and Treg/Teff ratios were not described in those previous reports. 
Although increased Treg numbers does not proof their functional importance in 
association studies with human samples, we want to point out that Treg 
accumulation within the graft was important for tolerance in animal models (28). In 
addition, our method of FOXP3 staining is closely related to the epigenetical Treg 
detection via the Treg-specific demethylated region (TSDR) and the TSDR 
methylation status correlated closely with stability and function of true Tregs (29). 
Our findings also partially resemble what has been described in patients converted 
from tacrolimus to sirolimus (30). In this study, intrahepatic FOXP3+ cells 
increased following tacrolimus discontinuation, although it is unclear if these 
changes followed a similar kinetic pattern to what we observed here and whether 
they were also associated to differences in immune activation and exhaustion 
gene markers (30). 
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Due to the limited amount of biomaterial in prospective human studies we cannot 
provide data of functionality and allo-reactivity of the adaptive immune system. 
Only a small number of immune cell subsets can be analyzed in graft biopsies, 
and direct in-vitro assays if global functionality cannot be performed when 
employing conventional clinical liver biopsies. Furthermore, PBMCs do not provide 
a suitable surrogate, as there are often disparities between intragraft immune 
responses and those detected in the circulation (20, 21, 23). To overcome these 
limitations we applied the gene expression analysis that assesses immunological 
changes of infiltrating cell types and graft stroma cells and correlated the data with 
the long-term clinical outcome. This is in line with recent results of the molecular 
microscope approach, in which histological data is complemented with expression 
data (24). 
The bi-phasic changes in graft infiltrating Tregs and intrahepatic expression of 
immune regulatory as well as endothelial-associated gene expression reported 
here point to miscellaneous  pathways that could be involved in the long-term 
maintenance of SOT beyond year 1. While the portal infiltrate expansion seen at 
year 1 is accompanied by an increase of Tregs, this inflammation does not lead to 
increased transaminases, or rejection suggesting a balanced inflammation. At year 
three expression analysis points to lower immune activation with less endothelial 
activation and a return of Treg numbers to baseline. As the immune infiltrates did 
not disappear, this could involve other tolerance mechanisms such as immune 
exhaustion (25). In this regard it is also interesting to note that there was a trend to 
an increased CD4+/CD8+ ratio in contrast to the decreased  CD4+/CD8+ ratio seen 
in acute rejection (20).  
  It is noteworthy that before IS withdrawal no differences in Treg/Teff ratio and 
pro-inflammatory gene expression were noted between tolerant and non-tolerant 
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HCV-negative recipients (17). This suggests that sequential analyses are essential 
to understand the mechanisms at play during SOT acquisition. In this regard, 
biomarkers predictive of IS withdrawal outcome, rather than a true fingerprint of 
SOT, are more likely to constitute biomarkers of a state conducive to tolerance 
once IS drugs are discontinued. The lack of longitudinal changes of the respective 
T cell populations in peripheral blood supports the notion, that intrahepatic 
immunological changes are not mirrored in the blood (20, 21, 23). This 
emphasizes the need to access the allograft itself to accurately monitor the SOT 
state.  
In short, we report here for the first time that in human liver transplant recipients 
SOT is characterized by persistent portal infiltrates with a benign clinical course 
without longitudinal evidence of relevant graft damages. This histological pattern 
points to a long-lasting immunological interplay of the recipient with the graft, 
which involves early increased Treg numbers and later a down-regulation of 
immune response genes. 
 Our data has important clinical and mechanistic implications for the design of 
future diagnostic and therapeutic clinical studies aiming at the achievement of 
allograft tolerance clinical organ transplantation.  
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Table 1. Baseline characteristics of the patients included in the study 
 
*All patients were HCV-RNA undetectable at the time of weaning 
 
 
Table 2: Intrahepatic immunophenotyping of portal infiltrates liver biopsies 
of non-HCV patients before and after weaning of immunosuppressants. 
 
pre-
weaning 
1 year 
SOT 
3 years 
SOT Global 
p-value 
1 y SOT vs 
pre-weaning 
3 y SOT vs 
1 y SOT 
3y SOT 
vs pre-
weaning 
 
mean (SD) mean (SD) 
mean 
(SD) 
p-value 
(diff.) 1 
p-value 
(diff.) 1 
p-value 
(diff.) 1 
Number of 
biopsies 15 14 12     
Infiltrate size 
[mm²] 
0.018 
(0.009) 
0.029 
(0.016) 
0.041 
(0.027) 0.002 0.032 (1.67) 0.35 (1.40) 
0.0002 
(2.33) 
CD4+ density 
[cells per mm²] 1304 (407) 
1511 
(559) 
1475 
(702) 0.72 1.00 (1.07) 1.00 (0.94) 
1.00 
(1.01) 
CD8+ density 
[cells per mm²] 988 (365) 
1089 
(366) 923 (423) 0.41 1.00 (1.04) 0.55 (0.83) 
0.95 
(0.86) 
CD4+FOXP3+ 44 (25) 62 (26) 47 (41) 0.042 0.038 (1.44) 0.095 1.00 
Characteristic 
Tolerant 
group 
n=24 
mean ± SD 
Non-tolerant 
group 
N=14 
mean ± SD 
Age at weaning start (years) 60.7±10.9 58.4±7.8 
Gender (% male) 83.3 64.3 
Time from transplant to minimization start (months) 137.5±43.6 79.7±28.9 
Donor age (years) 36.8±16.3 41.1±22.7 
Immunosuppressive therapy at weaning start (no. of 
patients) 
  
 Tacrolimus 3 7 
 Cyclosporin A 9 5 
 Mycophenolate 6 0 
 Azathioprine 1 0 
 Tacrolimus + mycophenolate 2 0 
 Cyclosporin A + mycophenolate 3 2 
Liver function tests at weaning start   
 Aspartate aminotransferases (U/L) 26.0±9.2 34.7±33.1 
 Alanine aminotransferases (U/L) 25.5±12.6 37.1±53.1 
 Gamma-glutamyl transpeptidase (U/L) 47.3±43.7 37.2±43.7 
 Alkaline phosphatase (U/L) 168.2±72 153.8±67.9 
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density [cells 
per mm²] 
(0.66) (0.96) 
CD4+ / CD8+ 
ratio 1.41 (0.40) 
1.41 
(0.29) 
1.60 
(0.28) 0.26 1.00 (1.02) 0.42 (1.14) 
0.39 
(1.16) 
Treg / CD4+ + 
CD8+ ratio 
0.019 
(0.011) 
0.024 
(0.009) 
0.018 
(0.010) 0.064 0.33 (1.34) 
0.041 
(0.71) 
1.00 
(0.96) 
Treg / CD4+ 
ratio 
0.034 
(0.020) 
0.043 
(0.018) 
0.029 
(0.016) 0.021 0.11 (1.33) 
0.009 
(0.66) 
0.94 
(0.88) 
Treg / CD8+ 
ratio 
0.047 
(0.027) 
0.057 
(0.018) 
0.046 
(0.026) 0.15 0.42 (1.35) 0.15 (0.77) 
1.00 
(1.04) 
 
(diff)1 – estimated fold-differences between the group means derived from linear mixed-effects 
models of log-transformed data. P-values refer to analysis with linear mixed-effects models of non-
transformed data except for infiltrate size, where log-transformation was used to correct for 
skewness of the distribution. Significant values (p<0.05) are highlighted in bold. Abbreviations: 
SOT: spontaneous operational tolerance. 
 
Table 3: Flow cytometric analysis of PBMC of non-HCV patients before and 
after weaning of immunosuppressants. 
 pre-weaning 1 year SOT 3 years SOT Global  
p-value 
 mean (SD) mean (SD) mean (SD) 
Number of samples 6* 12 5**  
CD3+% of lymphocytes 68.2 (12.4) 72.1 (7.4) nd 0.16 
CD4+% of CD3+ 50.5 (8.1) 44 (16.2) 40.2 (12.9) 0.37 
CD8+% of CD3+ 28.3 (8.2) 31.1 (7.7) nd 0.15 
CD4+CD25+FOXP3+% of CD4+ 7.1 (2.5) 5.8 (2.4) 5.5 (1.9) 0.097 
CD4+/ CD8+ ratio 1.9 (0.6) 1.6 (1.0) nd 0.25 
 
*
 n=9 for CD4+CD25+FOXP3+%; ** n=7 for CD4+CD25+FOXP3+%. 
Abbreviations: nd: not determined; SOT: spontaneous operational tolerance.  
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Table 4:  Significant differences in gene expression in sequentially collected 
liver tissue samples 
 Gene Official name 
Longitudinal analysis of SOT patients 
Rejection 
vs 
pre-Weaning Global  
p-value 
1 year 
SOT 
vs 
pre-
Weaning 
3 years 
SOT 
vs 
1 year 
SOT 
3 year SOT 
vs 
pre-
Weaning 
Im
m
u
n
o
-
re
gu
la
tio
n
 
m
a
rk
er
s
 CD244 CD244 molecule, natural killer cell receptor 2B4 0.018 
1.01 
(1.00) 
-1.46 
(0.042) 
-1.44 
(0.016) 
nd 
FOXP3 forkhead box P3 0.009 2.25 
(0.013) 
-2.52 
(0.003) 
-1.12 (1.00) 1.74 (0.006) 
Re
jec
tio
n
 
m
a
rk
er
s
 
CD52 CD52 molecule 0.004 -1.13 
(1.00) 
-1.58 
(0.037) 
-1.78 
(0.0008) 
-1.21 (0.29) 
 CXCL10 chemokine (C-X-C motif) ligand 10 0.22 
1.15 
(1.00) 
-1.46 
(0.26) 
-1.27 (0.64) 1.77 (0.004) 
 CXCL9 chemokine (C-X-C motif) ligand 9 0.17 
1.54 
(0.30) 
-1.62 
(0.19) 
-1.05 (1.00) 1.72 (0.009) 
 GPNMB glycoprotein (transmembrane) nmb 0.039 
1.39 
(0.20) 
-1.63 
(0.018) 
-1.18 (0.87) 1.03 (0.98) 
 IL32 interleukin 32 0.040 1.81 
(0.020) 
-1.56 
(0.13) 
1.16 (1.00) 1.08 (0.28) 
 IRF1 interferon regulatory factor 1 0.27 
1.37 
(0.40) 
-1.38 
(0.39) 
-1.00 (1.00) 1.19 (0.027) 
 STAT1 signal transducer and 
activator of transcription 1 0.038 
1.51 
(0.18) 
-1.83 
(0.017) 
-1.22 (0.92) 1.37 (0.008) 
 UBD ubiquitin D 0.066 2.04 
(0.069) 
-1.99 
(0.082) 
1.03 (1.00) 2.98 (0.016) 
th
e
lia
l c
e
ll 
m
a
rk CDH5 cadherin 5, type 2 0.038 1.3 
(0.10) 
-1.40 
(0.020) 
-1.07 (1.00) nd 
 ENPP2 
ectonucleotide 
pyrophosphatase/phospho
diesterase 2 
0.001 1.09 
(1.00) 
-1.70 
(0.0006) 
-1.57 
(0.0006) 
nd 
 MSL3 male-specific lethal 3 homolog 0.022 
1.12 
(1.00) 
-1.67 
(0.022) 
-1.50 
(0.047) 
nd 
 OPN3 opsin 3 <0.0001 1.08 
(0.80) 
-1.39 
(<0.0001) 
-1.29 
(<0.0001) 
nd 
 PAK2 p21 protein (Cdc42/Rac)-
activated kinase 2 0.043 
-1.02 
(1.00) 
-1.15 
(0.17) 
-1.17 
(0.033) 
nd 
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Estimated fold differences are derived from linear mixed-effects models for the SOT groups and 
from the ratio of the group means for Rejection vs paired pre-Weaning comparison following the 2-
∆∆CT
 method. Global p-values (derived from likelihood ratio tests) evaluate the association between 
timepoint and gene expression. In brackets are shown p-values from multiple comparisons with 
Bonferroni correction (for SOT groups) or from paired t-tests for the comparison of Rejection vs 
pre-Weaning groups. Significant values (p<0.05) are highlighted in bold. Abbreviations: nd: not 
determined; SOT: spontaneous operational tolerance. 
  
 RGS5 regulator of G-protein 
signaling 5 0.0041 
-1.74 
(0.10) 
-1.34 
(0.78) 
-2.32 
(0.0006) 
nd 
 S1PR1 sphingosine-1-phosphate 
receptor 1 0.013 
-1.43 
(0.095) 
-1.11 
(1.00) 
-1.58 
(0.005) 
nd 
 SELP selectin P 0.021 1.12 
(1.00) 
-1.60 
(0.019) 
-1.43 
(0.050) 
nd 
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Figure legends 
 
Figure 1: Multicolor immunofluorescence of human FFPE liver biopsies.  
(A) Representative histology from a tolerant patient at year 3 after successful IS 
withdrawal. Co-stainings for CD4 (green), CD8 (blue), FOXP3 (red), DAPI (white) 
of intrahepatic T cell infiltration were performed in FFPE liver biopsy section. Liver 
sinusoidal epithelial cells weakly express CD4 and can be distinguished from T 
cells by strength of CD4 expression, shape and localization of cells. The white line 
surrounds areas of portal infiltrations and excludes lumen of veins, arteries and 
bile ducts. (B) Secondary reagent control of representative portal tract in another 
biopsy from a tolerant patient. Autofluorescence and unspecific hepatocellular 
cytoplasmic staining (red) that resulted from biotin-streptavidin interaction in biotin 
rich hepatocytes caused the red-orange staining of hepatocytes. White dots are 
mostly autofluorescent erythrocytes. (C) Higher magnification of portal infiltrates 
with clear nuclear localization of the FOXP3 in CD4+ cells as demonstrate by (D) 
DAPI counterstaining (white) in higher magnification. White bars represent 100 µm 
(A, B) or 20 µm (C, D). 
 
Figure 2: Transient changes of the portal T cell compartment after 
successful immunosuppressant withdrawal. 
(A) Size of portal infiltrates in protocol liver biopsies before, 1 and 3 years after 
complete and successful immunosuppressant weaning. (B) Portal infiltration 
density of CD4+FOXP3+ Tregs. (C) Portal Tregs/CD4+ ratio. (D) Portal CD4+ (white 
bars) and CD8+ (grey bars) T cell infiltration densities. (E) Mean relative changes 
of immunophenotyping during SOT liver biopsies and blood samples. Portal 
Tregs/CD4+ ratio (black line), peripheral blood Tregs/CD4+ ratio (grey line), portal 
infiltrate size (black dotted line), portal CD4+/CD8+ ratio (black dashed line). 
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Sample numbers for SOT groups are shown in Table 2. Statistical analyses of 
SOT groups were carried out with linear mixed-effects models. P-values were 
adjusted with Bonferroni correction for multiple comparisons. Data for infiltrate size 
were log-transformed (ln) in order to correct for skewness of the distribution. 
Spontaneous operational tolerance (SOT). 
 
Figure 3: Sequential changes in intrahepatic transcriptional markers in liver 
recipients undergoing immunosuppression withdrawal.  
Relative expression of FOXP3, CD244, PD1 and BATF (A), IL32, CD68, STAT1, 
GPNMB and CD52 (B), and CDH5, ENPP2, OPN3, PAK2, S1PR1, RGS5, SELP 
and MSL3 (C) in liver tissue samples collected from liver recipients before the 
initiation of IS weaning (pre-weaning), 1 year after complete IS discontinuation (1 
year SOT), and 3 years after complete IS discontinuation (3 years SOT). Data 
were obtained on a Fluidigm real-time PCR platform and are displayed as mean 
and standard deviation of -∆CQ. * p<0.05; ** p<0.01.  
  
 26 
 
Supplementary Material 
Supplementary Table 1: Availability of patient material for longitudinal 
immunophenotyping and gene expression analysis of SOT. 
IF pre-
weaning 
IF 1 year 
SOT 
IF 3 years 
SOT 
Lbx 5 years 
SOT PBMC 
Gene 
expression 
Pat. 1 + + +   + + 
Pat. 2 +   + +   + 
Pat. 3 +   + + + + 
Pat. 4 + + +   + + 
Pat. 5 + + +   + + 
Pat. 6 +     +     
Pat. 7 +         + 
Pat. 8 + + +   +   
Pat. 9 + + +   +   
Pat. 10 + + + + + + 
Pat. 11 + +     + + 
Pat. 12 + +     +   
Pat. 13 + + +   + + 
Pat. 14 + +     + + 
Pat. 15 + +     + + 
Pat. 16   + + +     
Pat. 17   + +       
Pat. 18   + +       
Pat. 19           + 
Pat. 20           + 
Pat. 21           + 
Pat. 22           + 
Pat. 23           + 
Pat. 24           + 
Abbreviations: SOT: spontaneous operational tolerance; Pat.: patient; IF: Immunofluorescence; 
Lbx: liver biopsy; PBMC: peripheral blood mononuclear cells. 
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Supplementary Table 2: Liver Histopathology Findings *  
Histological Evaluation 
pre-weaning 1 year SOT 3 years SOT 
paired ANOVA 
mean  (range) 
mean  
(range) 
mean  
(range) 
Lobular inflammation 0 (0-1) 0 (0-1) 1 (0-1) 0.186 
Central perivenulitis 0 0 (0-1) 0 (0-1) 0.585 
Portal inflammation 1 (0-2) 1 (0-1) 1 (0-1) 0.618 
Interface hepatitis 0 (0-1) 0 (0-1) 0 0.585 
Biliary lesions 0 (0-1) 0 (0-1) 0 (0-1) 0.682 
Bile duct loss 0 0 0 (0-1) 0.363 
Portal vein endothelitis 0 (0-1) 0 (0-1) 0 (0-1) 0.682 
Portal fibrosis 1 (0-1) 0 (0-1) 0 (0-3) 0.478 
Perisinusoidal fibrosis 0 (0-2) 0 (0-2) 1 (0-2) 0.187 
    * Data correspond to a central pathology analysis of liver transplant recipients in whom all 3 
sequential liver biopsies   (pre-weaning,1 year SOT and 3 years SOT) were available for evaluation 
(n=7 each). Spontaneous operational tolerance (SOT).  
Lobular inflammation: 0=no; 1=mild (sinusoidal cells and/or mild focal necrosis); 2=moderate 
(multiple necro-inflammatory foci); 3=marked (confluent or bridging necrosis). Central perivenulitis 
(with or without endothelitis): 0=no; 1=mild (patchy, focal perivenular inflammation); 2=moderate 
(perivenulitis in most central veins); 3=marked (confluent or bridging hepatocellular necrosis). 
Portal inflammation: 0=no; 1=mild (small groups of inflammatory cells); 2=moderate (>50% of portal 
tracts, expansive); 3=marked. Interface hepatitis: 0=no; 1=mild; 2=moderate; 3=severe. Bile duct 
lesions: 0=no; 1=minimal (intraepithelial inflammatory cells or abnormal colangiocytes); 
2=moderate (epithelial lesions in most of portal tracts, no destruction); 3=marked. Bile duct loss: 
0=no; 1=<50%; 2=>50%. Portal vein endothelitis: 0=no; 1=mild (minority of portal veins); 2=mild 
(most of the portal veins); 3=marked. Portal fibrosis: 0=no; 1=minimal (minority of portal tracts); 
2=moderate (most of the portal tracts, periportal expansion); 3=bridging fibrosis; 4=cirrhosis. 
Perisinusoidal fibrosis: 0=no; 1=Focal patchy; 2=Prominent. 
Abbreviations: SOT: spontaneous operational tolerance. 
 
Supplementary Table 3: Differences in gene expression in sequentially 
collected liver biopsy and PBMCtissue samples for longitudinal analysis of 
SOT. 
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 Gene Official name 
Longitudinal analysis of SOT patients 
Rejection 
vs 
pre-Weaning Global  
p-value 
1 year 
SOT 
vs 
pre-
Weaning 
3 years 
SOT 
vs 
1 year 
SOT 
3 year SOT 
vs 
pre-
Weaning 
Im
m
u
n
o
re
gu
la
tio
n
 
m
ar
ke
rs
 
CD244 CD244 molecule, natural killer cell receptor 2B4 0.018 
1.01 
(1.00) 
-1.46 
(0.042) 
-1.44 
(0.016) 
nd 
CD274 CD274 molecule 0.077 
1.07 
(1.00) 
-1.34 
(0.096) 
-1.25 (0.18) nd 
CD3 CD3e molecule, epsilon 0.61 
1.36 
(1.00) 
-1.40 
(1.00) 
-1.03 (1.00) nd 
CTLA4 cytotoxic T-lymphocyte-
associated protein 4 0.72 
1.16 
(1.00) 
-1.37 
(1.00) 
-1.18 (1.00) nd 
FOXP3 forkhead box P3 0.009 
2.25 
(0.013) 
-2.52 
(0.003) 
-1.12 (1.00) 1.74 (0.006) 
IL10 interleukin 10 0.70 
1.17 
(1.00) 
-1.39 
(1.00) 
-1.18 (1.00) nd 
LAG3 lymphocyte-activation gene 3 0.37 
1.50 
(0.51) 
-1.41 
(0.72) 
1.07 (1.00) nd 
PD1 arogenate dehydratase 3 0.054 
1.59 
(0.21) 
-1.92 
(0.030) 
-1.21 (1.00) nd 
TIM3 hepatitis A virus cellular 
receptor 2 (HAVCR2) 0.089 
1.09 
(1.00) 
-1.52 
(0.12) 
-1.39 (0.19) nd 
BATF 
basic leucine zipper 
transcription factor, ATF-
like 
0.074 
1.52 
(0.32) 
-1.86 
(0.047) 
-1.22 (1.00) nd 
Re
jec
tio
n
 
m
a
rk
er
s
 
CD19 CD19 molecule 0.56 
-1.24 
(1.00) 
-1.29 
(1.00) 
-1.60 (0.84) nd 
CD34 CD34 molecule 0.10 
-1.08 
(1.00) 
-1.30 
(0.45) 
-1.41 
(0.090) 
nd 
CD68 CD68 molecule 0.050 
1.26 
(0.57) 
-1.57 
(0.029) 
-1.25 (0.42) nd 
CCL19 chemokine (C-C motif) ligand 19 0.19 
-1.47 
(0.87) 
-1.24 
(1.00) 
-1.83 (0.18) 1.14 (0.82) 
CD52 CD52 molecule 0.004 -1.13 -1.58 -1.78 -1.21 (0.29) 
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(1.00) (0.037) (0.0008) 
CD8A CD8a molecule 0.39 
1.35 
(1.00) 
-1.54 
(0.49) 
-1.14 (1.00) 1.06 (0.38) 
CXCL10 chemokine (C-X-C motif) ligand 10 0.22 
1.15 
(1.00) 
-1.46 
(0.26) 
-1.27 (0.64) 1.77 (0.004) 
CXCL9 chemokine (C-X-C motif) ligand 9 0.17 
1.54 
(0.30) 
-1.62 
(0.19) 
-1.05 (1.00) 1.72 (0.009) 
DHRS9 dehydrogenase/reductase (SDR family) member 9 0.086 
1.68 
(0.11) 
-1.69 
(0.099) 
-1.01 (1.00) 1.28 (0.13) 
GBP2 guanylate binding protein 2, interferon-inducible 0.33 
1.18 
(0.69) 
-1.23 
(0.41) 
-1.04 (1.00) 1.05 (0.59) 
GPNMB glycoprotein (transmembrane) nmb 0.039 
1.39 
(0.20) 
-1.63 
(0.018) 
-1.18 (0.87) 1.03 (0.98) 
IL18BP interleukin 18 binding protein 0.18 
1.09 
(1.00) 
-1.43 
(0.26) 
-1.31 (0.41) -1.08 (0.90) 
IL32 interleukin 32 0.040 
1.81 
(0.020) 
-1.56 
(0.13) 
1.16 (1.00) 1.08 (0.28) 
IRF1 interferon regulatory factor 1 0.27 
1.37 
(0.40) 
-1.38 
(0.39) 
-1.00 (1.00) 1.19 (0.027) 
LYZ lysozyme (renal 
amyloidosis) 0.32 
1.13 
(1.00) 
-1.29 
(0.38) 
-1.14 (1.00) 1.21 (0.20) 
MMP9 matrix metallopeptidase 9 0.44 
1.46 
(0.73) 
-1.45 
(0.73) 
1.01 (1.00) 1.03 (0.97) 
STAT1 signal transducer and 
activator of transcription 1 0.038 
1.51 
(0.18) 
-1.83 
(0.017) 
-1.22 (0.92) 1.37 (0.008) 
TAP1 
transporter 1, ATP-binding 
cassette, sub-family B 
(MDR/TAP) 
0.075 
1.46 
(0.082) 
-1.45 
(0.092) 
1.01 (1.00) 1.19 (0.094) 
TOP2A topoisomerase (DNA) II 
alpha 0.10 
1.51 
(0.68) 
-2.13 
(0.076) 
-1.41 (0.74) 1.29 (0.22) 
UBD ubiquitin D 0.066 
2.04 
(0.069) 
-1.99 
(0.082) 
1.03 (1.00) 2.98 (0.016) 
En
do
th
el
ia
l 
ce
ll 
m
ar
ke
rs
 
ADCY4 adenylate cyclase 4 0.39 
1.16 
(1.00) 
-1.32 
(0.49) 
-1.14 (1.00) nd 
CDH5 cadherin 5, type 2 0.038 
1.3 
(0.10) 
-1.40 
(0.020) 
-1.07 (1.00) nd 
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Estimated fold differences are derived from linear mixed-effects models for the SOT groups and 
from the ratio of the group means for Rejection vs paired pre-Weaning comparison following the 2-
∆∆CT
 method. Global p-values (derived from likelihood ratio tests) evaluate the association between 
timepoint and gene expression. In brackets are shown p-values from multiple comparisons with 
Bonferroni correction (for SOT groups) or from paired t-tests for the comparison of Rejection vs 
COL4A1 collagen, type IV, alpha 1 0.52 
1.22 
(1.00) 
-1.25 
(0.81) 
-1.03 (1.00) nd 
ENPP2 
ectonucleotide 
pyrophosphatase/phospho
diesterase 2 
0.001 
1.09 
(1.00) 
-1.70 
(0.0006) 
-1.57 
(0.0006) 
nd 
HSPG2 heparan sulfate proteoglycan 2 0.66 
1.08 
(1.00) 
-1.11 
(1.00) 
-1.03 (1.00) nd 
IGFBP7 insulin-like growth factor binding protein 7 0.19 
-1.08 
(1.00) 
-1.25 
(0.71) 
-1.35 (0.20) nd 
LAMB1 laminin, beta 1 0.53 
-1.04 
(1.00) 
-1.12 
(1.00) 
-1.16 (0.81) nd 
MFNG 
MFNG O-fucosylpeptide 3-
beta-N-
acetylglucosaminyltransfer
ase 
0.14 
1.19 
(1.00) 
-1.44 
(0.12) 
-1.22 (0.64) nd 
MLL3 myeloid/lymphoid or 
mixed-lineage leukemia 3 0.22 
1.15 
(0.29) 
-1.14 
(0.33) 
1.01 (1.00) nd 
MSL3 male-specific lethal 3 homolog 0.022 
1.12 
(1.00) 
-1.67 
(0.022) 
-1.50 
(0.047) 
nd 
OPN3 opsin 3 <0.0001 
1.08 
(0.80) 
-1.39 
(<0.0001) 
-1.29 
(<0.0001) 
nd 
PAK2 p21 protein (Cdc42/Rac)-
activated kinase 2 0.043 
-1.02 
(1.00) 
-1.15 
(0.17) 
-1.17 
(0.033) 
nd 
RGS5 regulator of G-protein 
signaling 5 0.0041 
-1.74 
(0.10) 
-1.34 
(0.78) 
-2.32 
(0.0006) 
nd 
S1PR1 sphingosine-1-phosphate 
receptor 1 0.013 
-1.43 
(0.095) 
-1.11 
(1.00) 
-1.58 
(0.005) 
nd 
SELP selectin P 0.021 
1.12 
(1.00) 
-1.60 
(0.019) 
-1.43 
(0.050) 
nd 
TRPV2 
transient receptor potential 
cation channel, subfamily 
V, member 2 
0.21 
1.39 
(0.21) 
-1.27 
(0.56) 
1.09 (1.00) nd 
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pre-Weaning groups. Significant values (p<0.05) are highlighted in bold. Abbreviations: nd: not 
determined; SOT: spontaneous operational tolerance. 
 
Supplementary Figure 1: Representative flow cytometry and gating strategy 
for sequentially collected blood samples. 
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